|Other Names||EF-hand domain-containing protein D2, Swiprosin-1, EFHD2, SWS1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP9285b was selected from the C-term region of human EFHD2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||May regulate B-cell receptor (BCR)-induced immature and primary B-cell apoptosis. Plays a role as negative regulator of the canonical NF-kappa-B-activating branch. Controls spontaneous apoptosis through the regulation of BCL2L1 abundance.|
|Cellular Location||Membrane raft. Note=In a mouse immature B-cell line WEHI-231.|
|Tissue Location||Found in lymphocytes; preferentially expressed in CD8+ cells.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
EFHD2 may regulate B-cell receptor (BCR)-induced immature and primary B-cell apoptosis. EFHD2 plays a role as negative regulator of the canonical NF-kappa-B-activating branch. This protein controls spontaneous apoptosis through the regulation of BCL2L1 abundance.
Thylur,R.P., et.al., J. Cell. Biochem. 108 (3), 705-715 (2009)Martins-de-Souza,D., et.al., Eur Arch Psychiatry Clin Neurosci 259 (3), 151-163 (2009)Avramidou,A., et.al., Cell Death Differ. 14 (11), 1936-1947 (2007)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.